Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2022–2033
2.3 Market Size & Forecast, By Segmentation, 2022–2033
2.3.1 Market Size By Product Type
2.3.2 Market Size By Application
2.3.3 Market Size By Therapy Type
2.3.4 Market Size By Patient Age Group
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Epidemiology & Patient Population Metrics
4.1.1 Overview
4.1.2 Prevalence of AATD by Region (per 100,000 population)
4.1.3 % Patients Diagnosed vs. Undiagnosed
4.1.4 Incidence of Severe vs. Moderate AATD Cases
4.1.5 Age & Gender Distribution of AATD Patients
4.2 Diagnosis & Screening Metrics
4.2.1 Overview
4.2.2 % Patients Diagnosed via Genetic Testing vs. Phenotypic Analysis
4.2.3 Average Time from Symptom Onset to Diagnosis (Years)
4.2.4 Adoption Rate of Newborn Screening Programs (%)
4.2.5 % Misdiagnosis Rate and Impact on Disease Progression
4.3 Treatment & Therapy Metrics
4.3.1 Overview
4.3.2 % Patients Receiving Augmentation Therapy vs. Standard Care
4.3.3 Average Dose Frequency and Treatment Duration (mg/kg/week or month)
4.3.4 Adherence Rate to Therapy (%)
4.3.5 % Patients Experiencing Clinical Improvements (Lung Function, Liver Enzyme Stabilization)
4.4 Pipeline & R&D Metrics
4.4.1 Overview
4.4.2 Number of AATD Therapeutics in Clinical Trials (Phase I, II, III)
4.4.3 % Share of Gene Therapy, Enzyme Replacement, and Small Molecule Approaches
4.4.4 Avg. Time from Clinical Trial Initiation to Regulatory Submission (Years)
4.4.5 Success Rate of Clinical Trials by Therapeutic Type
4.5 Market Access & Reimbursement Metrics
4.5.1 Overview
4.5.2 % Coverage of Augmentation Therapy under Insurance Programs
4.5.3 Average Out-of-Pocket Cost per Patient per Year (USD)
4.5.4 Reimbursement Approval Rate by Country (%)
4.5.5 Impact of Government Programs or Orphan Drug Incentives on Treatment Adoption
5. Alpha-1 Antitrypsin Deficiency Market Segmental Analysis & Forecast, By Product Type, 2022 – 2033, Value (USD Billion)
5.1 Introduction
5.2 Augmentation Therapy
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2022 – 2033
5.3 Bronchodilators
5.4 Corticosteroids
5.5 Oxygen Therapy
6. Alpha-1 Antitrypsin Deficiency Market Segmental Analysis & Forecast, By Application, 2022 – 2033, Value (USD Billion)
6.1 Introduction
6.2 Hospitals
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2022 – 2033
6.3 Specialty Clinics
6.4 Pharmacies
7. Alpha-1 Antitrypsin Deficiency Market Segmental Analysis & Forecast, By Therapy Type, 2022 – 2033, Value (USD Billion)
7.1 Introduction
7.2 Intravenous Therapy
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2022 – 2033
7.3 Inhalation Therapy
8. Alpha-1 Antitrypsin Deficiency Market Segmental Analysis & Forecast, By Patient Age Group, 2022 – 2033, Value (USD Billion)
8.1 Introduction
8.2 Adult
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2022 – 2033
8.3 Pediatric
9. Alpha-1 Antitrypsin Deficiency Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Product Type, 2022 – 2033
9.2.3 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Application, 2022 – 2033
9.2.4 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Therapy Type, 2022 – 2033
9.2.5 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Patient Age Group, 2022 – 2033
9.2.6 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Country, 2022 – 2033
9.2.6.1 USA
9.2.6.2 Canada
9.3 Europe
9.3.1 Key Trends
9.3.2 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Product Type, 2022 – 2033
9.3.3 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Application, 2022 – 2033
9.3.4 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Therapy Type, 2022 – 2033
9.3.5 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Patient Age Group, 2022 – 2033
9.3.6 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Country, 2022 – 2033
9.3.6.1 Germany
9.3.6.2 UK
9.3.6.3 France
9.3.6.4 Italy
9.3.6.5 Spain
9.3.6.6 Russia
9.3.6.7 Poland
9.3.6.8 Rest of Europe
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Product Type, 2022 – 2033
9.4.3 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Application, 2022 – 2033
9.4.4 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Therapy Type, 2022 – 2033
9.4.5 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Patient Age Group, 2022 – 2033
9.4.6 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Country, 2022 – 2033
9.4.6.1 China
9.4.6.2 India
9.4.6.3 Japan
9.4.6.4 South Korea
9.4.6.5 Australia
9.4.6.6 ASEAN Countries
9.4.6.7 Rest of Asia-Pacific
9.5 Latin America
9.5.1 Key Trends
9.5.2 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Product Type, 2022 – 2033
9.5.3 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Application, 2022 – 2033
9.5.4 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Therapy Type, 2022 – 2033
9.5.5 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Patient Age Group, 2022 – 2033
9.5.6 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Country, 2022 – 2033
9.5.6.1 Brazil
9.5.6.2 Argentina
9.5.6.3 Mexico
9.5.6.4 Colombia
9.5.6.5 Rest of Latin America
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Product Type, 2022 – 2033
9.6.3 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Application, 2022 – 2033
9.6.4 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Therapy Type, 2022 – 2033
9.6.5 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Patient Age Group, 2022 – 2033
9.6.6 Alpha-1 Antitrypsin Deficiency Market Size & Forecast, By Country, 2022 – 2033
9.6.6.1 UAE
9.6.6.2 Saudi Arabia
9.6.6.3 Qatar
9.6.6.4 Egypt
9.6.6.5 South Africa
9.6.6.6 Rest of Middle East & Africa
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6.1 Grifols S.A.
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Takeda Pharmaceutical Company Limited
10.6.3 CSL Behring
10.6.4 Kamada Pharmaceuticals
10.6.5 GlaxoSmithKline plc
10.6.6 AstraZeneca Plc
10.6.7 Boehringer Ingelheim International GmbH
10.6.8 Pfizer Inc.
10.6.9 Arrowhead Pharmaceuticals, Inc.
10.6.10 Vertex Pharmaceuticals Incorporated
10.6.11 Mereo Biopharma Group plc
10.6.12 Dicerna Pharmaceuticals, Inc.
10.6.13 Inhibrx, Inc.
10.6.14 Teva Pharmaceutical Industries Ltd.
10.6.15 LFB Biomedicaments S.A.
10.6.16 Alnylam Pharmaceuticals, Inc.
10.6.17 Sanofi S.A.
10.6.18 CHIESI Farmaceutici S.p.A.
10.6.19 Epicrispr Biotechnologies, Inc.
10.6.20 Intellia Therapeutics, Inc.
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions on Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
